This bill amends the Uniform Controlled Dangerous Substances Act in Oklahoma by adding several new substances to Schedules I and IV, which categorize controlled substances. It introduces a variety of opiates, opium derivatives, hallucinogenic substances, and other compounds with stimulant or depressant effects, including Adinazolam, Meclonazepam, N-methylclonazepam, Bromazolam, Flunitrazolam, Nitrazolam, Pyrazolam, and Zapizolam. The bill also modifies definitions related to the Anti-Drug Diversion Act and clarifies that certain industrial uses of Gamma-Butyrolactone and related compounds are excluded from being classified as controlled substances if marketed for legitimate industrial purposes.

Additionally, the bill updates the classification and regulation of various compounds with potential for abuse, introducing new definitions for substances such as benzoylindoles and cyclopropoylindoles, and detailing their chemical structures. It modifies existing language to exclude certain FDA-approved prescription drugs from being classified as Schedule I controlled substances, provided they are designated or rescheduled by the DEA. The bill also adds new controlled substances like Lormetazepam and Nifoxipam while removing references to "Ketone" in the context of Carbazole and Benzimidazole. It clarifies the roles of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control and the State Board of Pharmacy in regulating these substances, with the bill set to take effect on November 1, 2026.